#1 Clinical Trials Search in Europe

Human Papillomavirus Type 16 L1 Protein

This article summarizes several clinical trials investigating the use of Human Papillomavirus (HPV) vaccines containing HPV Type 16 L1 Protein. These studies aim to evaluate the safety, efficacy, and immunogenicity of HPV vaccines in various populations, including children, adolescents, adults, and immunocompromised individuals. The trials explore different dosing regimens, timing of vaccination, and potential benefits in preventing HPV-related diseases and cancers.

Table of Contents

What is HPV16?

Human Papillomavirus Type 16 (HPV16) is one of several types of HPV that can cause health problems in humans. HPV16 is considered a high-risk type because it can lead to the development of certain cancers, including cervical, anal, and head and neck cancers.[1]

About the Vaccine

The vaccine containing Human Papillomavirus Type 16 L1 Protein is part of a broader vaccine called Gardasil 9. This vaccine protects against nine types of HPV, including HPV16. Gardasil 9 is what’s known as a 9-valent vaccine, meaning it targets nine different HPV types.[2]

The full name of the vaccine is “Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)”. It’s important to understand some key terms:

  • Recombinant: This means the vaccine is made using genetic engineering techniques.
  • Adsorbed: The vaccine components are attached to an adjuvant (a substance that enhances the body’s immune response) to make the vaccine more effective.

How the Vaccine Works

The vaccine works by introducing a protein that looks like part of the HPV virus (specifically, the L1 protein) into your body. This protein is not the actual virus and cannot cause an HPV infection. Instead, it triggers your immune system to produce antibodies against HPV. If you’re later exposed to the real virus, your body will recognize it and be ready to fight it off.[3]

Who Should Get Vaccinated

The vaccine is recommended for both males and females. While specific age recommendations may vary, studies have looked at its use in different age groups:

  • Children and adolescents aged 9-14 years[1]
  • Young adults aged 16-26 years[1]
  • Adults up to 45 years of age[4]

It’s particularly important for people who haven’t been exposed to HPV yet, which is why vaccination is often recommended before becoming sexually active.

Dosing Schedule

The typical vaccination schedule involves three doses given over six months. However, research is also looking at extended dosing schedules and two-dose regimens for younger individuals.[1]

Effectiveness

Studies have shown that the vaccine is highly effective in preventing HPV infections and related diseases. It can help prevent:

  • Persistent HPV infections
  • Cervical, vulvar, and vaginal precancers
  • Anal infections and precancers
  • Genital warts

Research is ongoing to assess its effectiveness in preventing oral HPV infections as well.[3]

Safety

The vaccine has been extensively tested and is considered safe. Like all vaccines, it can cause some side effects, most commonly:

  • Pain, swelling, or redness at the injection site
  • Headache
  • Fever

Serious side effects are rare. As with any medical treatment, it’s important to discuss potential risks and benefits with your healthcare provider.[2]

Ongoing Research

Several clinical trials are currently underway to further study the vaccine’s effectiveness and potential uses. These include:

  • Evaluating extended dosing intervals in children and adolescents[1]
  • Studying its use in immunocompromised individuals[2]
  • Assessing its effectiveness in preventing oral HPV infections in adult males[3]
  • Investigating its potential in preventing HPV-related diseases in individuals who have already been treated for high-grade cervical lesions[4]

These ongoing studies aim to optimize the use of the vaccine and potentially expand its benefits to more people.

Trial Focus Population Key Objectives Vaccine Type
Extended dosing intervals Children and adolescents 9-14 years, women 16-26 years Evaluate safety and immunogenicity of 2-dose vs 3-dose regimens 9-valent HPV vaccine (Gardasil 9)
Immunocompromised patients Children and adolescents over 9 years Assess immunogenicity in HIV-infected, transplant recipients, and post-chemotherapy patients 9-valent HPV vaccine (Gardasil 9)
Oral persistent infection prevention Adult males 20-45 years Evaluate efficacy in preventing oral HPV infections 9-valent HPV vaccine (Gardasil 9)
Men who have sex with men (MSM) MSM aged 19-26 years Assess vaccine effectiveness against anal HPV infections Bivalent HPV vaccine (Cervarix)
Post-stem cell transplantation Adult transplant recipients 18-45 years Compare early vs late vaccination timing after transplantation 9-valent HPV vaccine (Gardasil 9)
Vulvar high-grade lesions Women with vulvar HSIL Evaluate vaccine efficacy in preventing recurrence after treatment 9-valent HPV vaccine (Gardasil 9)
High-grade cervical lesions Women over 45 years Assess HPV clearance and recurrence prevention after treatment 9-valent HPV vaccine (Gardasil 9)

FAQ

  • What is the main purpose of these HPV vaccine clinical trials? The main purpose of these clinical trials is to evaluate the safety, efficacy, and immunogenicity of HPV vaccines containing HPV Type 16 L1 Protein in different populations. The studies aim to determine optimal dosing regimens, assess vaccine effectiveness in preventing HPV infections and related diseases, and explore potential benefits in various age groups and health conditions.
  • Who are the target populations for these HPV vaccine trials? The target populations vary across the trials but include children and adolescents aged 9-14 years, adult males aged 20-45 years, women over 45 years with high-grade cervical lesions, immunocompromised children and adolescents, and recipients of allogeneic stem cell transplantation. Some studies also focus on specific groups such as men who have sex with men (MSM) and women with vulvar high-grade squamous intraepithelial lesions.
  • What are some of the key outcomes being measured in these trials? Key outcomes being measured include antibody responses to HPV types, seroconversion rates, incidence of HPV-related infections and diseases, safety and tolerability of the vaccines, and long-term protection against HPV. Some trials also assess quality of life, sexual health, and cost-effectiveness of vaccination strategies.
  • Are there any special considerations for certain populations in these trials? Yes, there are special considerations for certain populations. For example, some trials focus on immunocompromised individuals, such as HIV-infected children and adolescents or stem cell transplant recipients. Other studies evaluate the effectiveness of vaccination in preventing recurrence of high-grade lesions in women or assessing optimal timing of vaccination after stem cell transplantation.
  • What types of HPV vaccines are being studied in these trials? The trials primarily focus on two types of HPV vaccines: the 9-valent HPV vaccine (Gardasil 9) and the bivalent HPV vaccine (Cervarix). These vaccines contain various HPV type proteins, including HPV Type 16 L1 Protein, and are designed to protect against multiple strains of HPV that can cause infections and related diseases.

Ongoing Clinical Trials on Human Papillomavirus Type 16 L1 Protein

  • Study on HPV Vaccine Timing for Patients After Stem Cell Transplantation Using Gardasil 9

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

Glossary

  • Human Papillomavirus (HPV): A group of viruses that can cause various infections and cancers, particularly affecting the genital areas and oral cavity.
  • L1 Protein: A major structural protein of HPV that forms the outer shell (capsid) of the virus and is used in HPV vaccines to stimulate an immune response.
  • Immunogenicity: The ability of a substance, such as a vaccine, to provoke an immune response in the body.
  • Seroconversion: The development of detectable antibodies in the blood directed against an infectious agent, indicating an immune response to vaccination or infection.
  • Geometric Mean Titer (GMT): A measure of the average concentration of antibodies in a group of subjects, used to assess the immune response to a vaccine.
  • High-grade Squamous Intraepithelial Lesion (HSIL): Abnormal, precancerous changes in the cells of the cervix, vulva, or other areas that may progress to cancer if left untreated.
  • Allogeneic Stem Cell Transplantation: A procedure where stem cells from a donor are transplanted into a recipient to treat various diseases, particularly blood and immune system disorders.
  • Persistent Infection: An infection that remains in the body for an extended period, often without causing immediate symptoms but potentially leading to health complications.
  • Recombinant Vaccine: A vaccine produced using genetic engineering techniques to create proteins that stimulate an immune response against specific pathogens.
  • Adverse Event (AE): Any unfavorable or unintended sign, symptom, or disease associated with the use of a medical treatment or procedure, including vaccines.

References

  1. http://clinicaltrials.eu/trial-id/2022-500256-37-00
  2. http://clinicaltrials.eu/trial-id/2022-501413-31-00
  3. http://clinicaltrials.eu/trial-id/2022-501974-21-00
  4. http://clinicaltrials.eu/trial/study-on-hpv-vaccine-after-treatment-for-high-grade-cervical-lesions-in-women-over-45/